title: Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis.
abstract: OBJECTIVE
  To describe the long-term effects of Hylan GF-20 viscosupplementation in patients with knee osteoarthritis and to identify factors predicting efficacy.
  
  
  METHODS
  One hundred and fifty-five patients (80 women and 75 men; mean age, 69 years) with symptomatic knee osteoarthritis each received three intraarticular Hylan GF-20 injections. Effectiveness, safety, and satisfaction were evaluated 7-14 months later based on a physician's examination and a five-item questionnaire. Radiological data (distribution and degree of joint space loss), size of the effusion (none, moderate, large), injection route (anterior, medial to the patella, or lateral to the patellar), and side effects were recorded. Factors predicting effectiveness were looked for by univariate analysis followed by multivariable analysis with adjustments on age, body mass index, gender, and time from treatment to questionnaire administration.
  
  
  RESULTS
  Satisfaction was good in 78% and 58.9% of the patients according to the physician examination and questionnaire, respectively. Safety was considered excellent or good in 96.2% of the patients. Factors significantly (P < 0.05) associated with a good outcome were a moderate effusion, injection lateral to the patella, joint space loss in a single compartment, and radiological meniscal calcinosis.
  
  
  CONCLUSIONS
  The factors predictive of a good response to Hylan GF-20 in this study need to be confirmed, and their impact quantitated, in prospective studies.
authors.affiliation: Rheumatology department, Centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France. thierry.conrozier@chu-lyon.fr
authors.forename: Thierry
authors.initials: T
authors.lastname: Conrozier
authors.forename: Pierre
authors.initials: P
authors.lastname: Mathieu
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Schott
authors.forename: Isabelle
authors.initials: I
authors.lastname: Laurent
authors.forename: Touria
authors.initials: T
authors.lastname: Hajri
authors.forename: Pierre
authors.initials: P
authors.lastname: Crozes
authors.forename: Pierre
authors.initials: P
authors.lastname: Grand
authors.forename: Henri
authors.initials: H
authors.lastname: Laurent
authors.forename: François
authors.initials: F
authors.lastname: Marchand
authors.forename: Francis
authors.initials: F
authors.lastname: Meignan
authors.forename: Eric
authors.initials: E
authors.lastname: Noel
authors.forename: Yves
authors.initials: Y
authors.lastname: Rozand
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Savoye
authors.forename: Eric
authors.initials: E
authors.lastname: Vignon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D017060:Patient Satisfaction; D016896:Treatment Outcome
chemical_list: C049816:hylan; D006820:Hyaluronic Acid